Risk for attention deficit hyperactivity disorder in alopecia areata patients: A nationwide case-control study - 14/03/26
Doi : 10.1016/j.annder.2025.103439
Y. Wohl a, b, c, ⁎ 
, J. Mashiah d, e, f, R. Wohl g, A. Maruani d, h, A. Bentov b, e, f
, J. Mashiah d, e, f, R. Wohl g, A. Maruani d, h, A. Bentov b, e, f a Faculty of Medicine, Ariel University, Israel
b Maccabi Health Services, Tel-Aviv, Israel
c Kahn Sagol Maccabi Research and Innovation Center, Maccabi Healthcare Services, Tel-Aviv, Israel
d Division of Dermatology, Pediatric Dermatology Unit, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel
e Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
f Department of Dermatology and Reference Center for Genodermatoses and Rare Skin Diseases (MAGEC), AP-HP, Paris University, Necker-Enfants Maladies Hospital, Paris Centre University, Imagine Institute, Paris, France
g Faculty of Medicine, Bar Ilan University, Israel
h University Hospital Center of Tours, Department of Dermatology, Unit of Pediatric Dermatology, Tours, France
⁎ Corresponding author at: Maccabi Health Services, Haarbaa ST 28, Tel-Aviv, Israel. Maccabi Health Services Haarbaa ST 28 Tel-Aviv Israel
Plan
© 2025
The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 153 - N° 1
Article 103439- mars 2026 Retour au numéro
Article précédent
- Development of a shared decision-making tool for systemic treatment in psoriasis
- A. Anelli, E. Sbidian, J.-F. Huon, S. Valyi, S. Barbarot, M. Beylot-Barry, C. Girard, D. Jullien, C. Paul, H. Aubert, French Psoriasis Research Group (GrPSO) of the French Society of Dermatology
- Myasthenia gravis induced by encorafenib and binimetinib for metastatic melanoma
- V. Groussin, H. Moumy, C. Coltoiu, G. Quéreux, M. Piroth
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?